SCHEMBL1133709

SCHEMBL1133709

CC(=O)c1cc(C#N)c(-c2ccc(Cl)cc2Cl)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
USP7 Q93009 1/20 0.43
CNR1 P21554 2/20 0.39
CNR2 P34972 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALPL P05186 7/20 0.38
GABRA1 P14867 4/20 0.37
GABRG2 P18507 4/20 0.37
GABRB3 P28472 4/20 0.37
GABRB2 P47870 3/20 0.37
GABRB1 P18505 1/20 0.36
MET P08581 1/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13731676 0.85 JAK2 (0.38) KDM4EUSP7MAPTGABRA1GABRG2
SCHEMBL1133647 0.81 MAPT (0.50) KDM4ECNR1CNR2MEN1LMNA
SCHEMBL1133645 0.81 MAPT (0.50) KDM4ECNR1CNR2MEN1LMNA
SCHEMBL13625298 0.79 CNR1 (0.41) CNR1CNR2MAPTALPLKDR
SCHEMBL15755455 0.76 BIRC5 (0.43)
SCHEMBL12880091 0.73 KDM4E (0.43) KDM4EMEN1LMNAGAAHPGD
SCHEMBL12019616 0.72 ALOX15 (0.47) KDM4EGAAHPGDKMT2AMAPT
SCHEMBL1133474 0.70 KDM4E (0.43) KDM4ECNR1CNR2MEN1LMNA
SCHEMBL30679520 0.70 KDM4E (0.43) KDM4ECNR1CNR2MEN1LMNA
SCHEMBL14670125 0.68 POLB (0.41) KDM4EMEN1LMNAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2285801-B1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-09 EP disclosed
EP-2285801-B1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-09 EP disclosed
US-8399668-B2 Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides NERVIANO MEDICAL SCIENCES S. R. L. (IT) 2013-03-19 US disclosed
US-8399668-B2 Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides NERVIANO MEDICAL SCIENCES S. R. L. (IT) 2013-03-19 US disclosed
US-8399668-B2 Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides NERVIANO MEDICAL SCIENCES S. R. L. (IT) 2013-03-19 US disclosed
EP-2285801-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES Nerviano Medical Sciences S.r.l. (IT) 2011-02-23 EP disclosed
US-20110040090-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-02-17 US disclosed
US-20110040090-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-02-17 US disclosed
US-20110040090-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-02-17 US disclosed
WO-2009133170-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-11-05 WO disclosed
WO-2009133170-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110040090-A1 PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES CDC7, CDK7, CDK17 KDM4E 342/4885USP7 194/4885CNR1 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.